|
|
Bioinformatics.org
|
![[?]](https://www.bioinformatics.org/images/icons/info.png)
|
|
Research
|
Online databases
Online analysis tools
Online education tools
|
|
Development
|
|
|
Forums
|
News & Commentary
Jobs Forum
(Career Center)
|
|
|
News & Commentary - Message forums
|
         
|
 |
|
Education: Webinar on generation of a dual-function multi-engager antibody for simultaneous targeting NK cells and tumor cells
Submitted by Bella Smith; posted on Friday, May 2, 2025
|
May 22, 2025 at 11:00 AM EDT (USA)
Register for Creative Biolabs' Webinar: https://www.creativebiolabs.net/generation-of-a-dual-function-multi-engager-antibody-for-simultaneous-targeting-nk-cells-and-tumor-cells.htm
The relentless pursuit of innovative cancer immunotherapies has unveiled natural killer (NK) cells as formidable agents in the fight against malignancies. While these innate immune cells possess inherent tumor-killing capabilities, their full potential remains constrained by regulatory mechanisms and tumor evasion strategies. At the forefront of this research stands ADAM17, a membrane-associated protease that functions as both a negative regulatory checkpoint in NK cells and a tumor-associated antigen overexpressed in various malignancies. Creative Biolabs is honored to invite Dr. Bruce Walcheck to introduce the Targeted ADAM17 Blocker and Killer (TABK), an ingenious multi-engager antibody complex that simultaneously enhances NK cell proliferation while directing these empowered immune cells to engage and eliminate ADAM17-expressing tumor cells. Join us to explore how this innovative approach leverages ADAM17's unique dual role to create a potent immunotherapeutic strategy with promising implications for cancer treatment.
During this webinar, we will discuss the following key points:
- NK cell-mediated natural cytotoxicity and antibody-dependent cellular cytotoxicity (ADCC)
- Utilizing NK cells to kill cancer cells
- ADAM17, a membrane-associated protease expressed by NK cells
- ADAM17 functions as a negative regulatory checkpoint in NK cells and is a tumor-associated antigen
- ADAM17 inhibition by the mAb Medi-1 enhances NK cells activation and proliferation
- Development of the multi-engager antibody complex Targeted ADAM17 Blocker and Killer (TABK)
- TABK selectively blocks ADAM17 in NK cells and synergizes with IL-15 stimulation to enhance NK cell activation and proliferation
- TABK engages ADAM17 overexpressed by various malignancies, linking NK cells to tumor cells to mediate their killing
|
|
Expanded view | Monitor forum | Save place
Start a new thread:
You have to be to post a reply.
|
|
![[Next-Generation Sequencing Book]](https://www.bioinformatics.org/images/ack_banners/NGS-Book-1-728x90.png)